Refine
Has Fulltext
- yes (155)
Is part of the Bibliography
- yes (155)
Year of publication
Document Type
- Journal article (101)
- Doctoral Thesis (47)
- Preprint (2)
- Report (2)
- Review (2)
- Book article / Book chapter (1)
Keywords
- Motoneuron (16)
- Spinale Muskelatrophie (11)
- BDNF (9)
- glycine receptor (8)
- spinal muscular atrophy (6)
- Actin (5)
- CNTF (5)
- SMN (5)
- hyperekplexia (5)
- motoneurons (5)
- neurons (5)
- startle disease (5)
- Ionenkanal (4)
- Maus (4)
- Nervenzelle (4)
- TrkB (4)
- Zellkultur (4)
- Axon (3)
- Ciliary neurotrophic factor (3)
- Entzündung (3)
- Glycin (3)
- Glycinrezeptor (3)
- Hippocampus (3)
- Hyperekplexie (3)
- Phospholipide (3)
- SMA (3)
- STAT3 (3)
- Spinal Muscular Atrophy (3)
- Stathmin (3)
- amyotrophic lateral sclerosis (3)
- ciliary neurotrophic factor (3)
- hippocampus (3)
- motoneuron (3)
- neurology (3)
- neuromuscular junction (3)
- synaptic vesicles (3)
- 3D cell culture (2)
- Apoptosis (2)
- BDNF stimulation (2)
- Bewegungsstörung (2)
- Cell culture (2)
- Cys-loop receptor (2)
- Drosophila melanogaster (2)
- Genexpression (2)
- Microtubules (2)
- Motoneuronenerkrankung (2)
- Myatrophische Lateralsklerose (2)
- NaV1.9 (2)
- Neurobiologie (2)
- Neurotrophic factors (2)
- Nociceptor (2)
- PLEKHG5 (2)
- RNA (2)
- Ribosom (2)
- Sap47 (2)
- Schmerzforschung (2)
- Schmerztherapie (2)
- Signaltransduktion (2)
- Spinal muscular atrophy (2)
- Stat3 (2)
- Synapse (2)
- Taufliege (2)
- Transcription (2)
- autophagy (2)
- axons (2)
- binding (2)
- cAMP (2)
- cortical neurons (2)
- drosophila melanogaster (2)
- glycine receptor autoantibodies (2)
- glycine uptake (2)
- growth cone (2)
- hnRNP R (2)
- hnRNP-R (2)
- hybridomas (2)
- immunoprecipitation (2)
- intracellular domain (2)
- ion channel (2)
- loss of function (2)
- melt electrowriting (2)
- motoneuron disease (2)
- mouse (2)
- mushroom body (2)
- neurofascin (2)
- neuropathic pain (2)
- neurotrophins (2)
- pain (2)
- phosphorylation (2)
- pmn (2)
- presynaptic hyperekplexia (2)
- receptor (2)
- spinal cord (2)
- structural disruption (2)
- synaptic inhibition (2)
- synaptic plasticity (2)
- trkB (2)
- 2-pore potassium channel (1)
- 3D cell cultures (1)
- 3D cultures (1)
- 3D electrophysiology (1)
- 3D microfiber (1)
- 3D model systems (1)
- 3D muscle (1)
- 3D neuronal networks (1)
- 3D tumor model (1)
- 3D-Zellkultur (1)
- 4-HNE (1)
- 7,8-dihydroxyflavone (7,8-DHF) (1)
- 7SK (1)
- ALS (1)
- AMPA (1)
- ASC-1 (1)
- Actin Dynamics (1)
- Aging (1)
- Alpha-synuclein oligomers (1)
- Alzheimer disease (1)
- Alzheimer's disease (1)
- Alzheimers disease (1)
- Alzheimer’s disease (1)
- Aminobuttersäure <gamma-> (1)
- Aminosäuren (1)
- Amyloid-beta oligomers; (1)
- Amyotrophe Lateralsklerose (1)
- Amyotrophic lateral sclerosis (1)
- Amyotrophic-lateral-sclerosis (1)
- Animal modell (1)
- ApoA-I D-4F (1)
- Asc-1 transporter (1)
- Associative learning (1)
- Astrocytes ; Schwann cells ; Interferon-gamma ; Fibroblast growth factor ; Cyclic AMP (1)
- Autism spectrum disorders (1)
- Autoantikörper (1)
- Axon Branching (1)
- Axon degeneration (1)
- Axon growth (1)
- Axonal transport (1)
- Axonaler Transport (1)
- BNDF (1)
- BSTA (1)
- Bag1 (1)
- Bildanalyse (1)
- Biologie (1)
- Brain (1)
- Brain-derived neurotrophic factor (1)
- C. elegans (1)
- C9orf72 (1)
- CNS (1)
- CNTF Sehnerv Retina Degeneration (1)
- CNTF optic nerve retina degeneration (1)
- COVID-19 (1)
- Ca\(^{2+}\)-Imaging (1)
- Ca\(_{v}\)2.2 (1)
- Calcium Imaging (1)
- Caspr2 (1)
- Cav2.2 (1)
- Cells (1)
- Cellular prion protein (1)
- Central nervous system (1)
- Chaperone (1)
- Chaperones (1)
- Co-culture (1)
- Contactin-assoziiertes Protein 2 (1)
- Cytochrom C (1)
- Cytochrom c (1)
- Cytochrome C (1)
- Cytokine (1)
- Cytokines (1)
- DAPI staining (1)
- DNA damage (1)
- DNA repeat expansion (1)
- DRD1 (1)
- DRG (1)
- Deeplearning (1)
- Dentate granule cells (1)
- Diabetic polyneuropathy (1)
- Diabetische Polyneuropathie (1)
- Dorsal root ganglion (1)
- Down syndrome (1)
- Drosophilia (1)
- Dynamics of ribosome assembly (1)
- E06 mAb (1)
- EAE (1)
- EGFR (1)
- ER dynamics in axon terminals (1)
- Embryonalentwicklung (1)
- Endoplasmatisches Retikulum (1)
- Erregbarkeit (1)
- Exercise (1)
- F-actin (1)
- FGF-5 (1)
- Facial Nerve Transection (1)
- Familial Alzheimers-disease (1)
- Fazialisläsion (1)
- Fear conditioning (1)
- Fibroblast Growth Factor (1)
- Funktionsverlust (1)
- GABA receptor (1)
- GABA-A receptor (1)
- GABA-Rezeptor (1)
- GABA\(_{A}\) (1)
- GABA\(_{A}\) receptor (1)
- GDNF (1)
- GPCR (1)
- Gedächtnis (1)
- Geruch (1)
- Glucocorticosteroide (1)
- Glutamatergic synapses (1)
- GlyR receptors (1)
- GlyRs (1)
- Glycintransporter 2 (GlyT2) (1)
- Golgi apparatus (1)
- Golgi-Apparat (1)
- Großhirnrinde (1)
- Guillain-Barre-Syndrome (1)
- H2O2 (1)
- Heterogene Ribonucleoproteine (1)
- Histon-Deacetylase (1)
- ICAM-1 (1)
- IGF-I (1)
- IGF1 (1)
- IgG4 (1)
- Ighmbp2 (1)
- Immunhistochemie (1)
- Immunoblot (1)
- Immunopanning (1)
- Induced pluripotent stem cells (1)
- Induzierte pluripotente Stammzelle (1)
- Inflammatory Pain (1)
- Inhibitorische Synapse (1)
- Inhibitory glycine receptor (1)
- Insulin-like Growth (1)
- Insulin-like-Growth-Factor-Binding-Protein-5 (1)
- Insulinlike Growth Factor (1)
- Integrated Defensive States (1)
- Interaction of 7SK with the Smn complex modulates snRNP production (1)
- Intermediate filaments (1)
- Isomer (1)
- JNK (1)
- Kalyx (1)
- Kalziumkanalagonisten (1)
- Kenyon cells (1)
- Kinasen (1)
- Knockdown (1)
- Knockout (1)
- Konformationsänderung (1)
- Kortikogenese (1)
- Krankheit (1)
- LIFR (1)
- LTP (1)
- Lacking neurofilaments (1)
- Laminin (1)
- Learning and memory (1)
- Lernen (1)
- Lysosomal storage disease (1)
- MAP1B (1)
- MND (1)
- MOC fibers (1)
- Mausmodell (1)
- Migration (1)
- Missense mutation (1)
- Molecular neuroscience (1)
- Morpholino (1)
- Motoneuron disease (1)
- Motoneuron-Krankheit (1)
- Motoneuronenerkrankungen (1)
- Motoneuronerkrankung (1)
- Motoneurons (1)
- Motor behaviour (1)
- Motor neuron disease (1)
- Motor neuron disease; Ciliary neurotrophic factor; Brain-derived neurotrophic factor; Animal models; Neurotrophic factors (1)
- Motorische Endplatte (1)
- Mouse model (1)
- Mus spretus (1)
- N-Typ Kalziumkanäle (1)
- N-type calcium channel (1)
- NGF gene family (1)
- NMDAR (1)
- NMJ (neuromuscular junction) (1)
- NMJ–neuromuscular junction (1)
- NTRK fusions (1)
- Natriumkanal (1)
- Nervennetz (1)
- Nervensystem (1)
- Neural Stem Cells (1)
- Neural circuits (1)
- Neurale Stammzellen (1)
- Neuritenwachstum (1)
- Neurodegeneration (1)
- Neurofilament (1)
- Neurogenese (1)
- Neuromuskuläre Endplatte (1)
- Neuronal ceroid lipofuscinosis (1)
- Neuronale Differenzierung (1)
- Neuronale Plastizität (1)
- Neurotropher Faktor (1)
- Neurotrophin (1)
- Neurotrophine (1)
- Object recognition (1)
- Optical coherence tomography (1)
- Oxidized Phospholipids (1)
- P75 Neurotrophin receptor (1)
- PDXP inhibitors (1)
- PKB/Akt phosphorylation (1)
- PTEN (1)
- Parkinson’s disease (1)
- Pathologie (1)
- Perianova, Irina (1)
- Periaqueductal gray (1)
- Phosphorylation (1)
- Pilzkörper (1)
- Plasma-membrane (1)
- Pleckstrin homology containing family member 5 (Plekhg5) (1)
- Progressive motor neuronopathy (1)
- Protein kinase B (1)
- Proteine (1)
- Proteintransport (1)
- Präsynaptische Hyperekplexie (1)
- R-Roscovitine (1)
- RHO (1)
- RNA splicing (1)
- RNA transport (1)
- RNA-binding proteins (1)
- ROCK (1)
- RSK2 (1)
- Raf (1)
- Raf <Biochemie> (1)
- Raf Kinasen (1)
- Raf Kinases (1)
- Raf-Kinase (1)
- Raf-Kinasen (1)
- Reprogrammming (1)
- Retinal degeneration (1)
- Rezeptor (1)
- Rictor-mTOR complex (1)
- Roscovitine (1)
- SAP47 gene (1)
- SARS-CoV- 2 (1)
- SLC6A5 (1)
- SLC7A10 (1)
- SMARD1 (1)
- SMN granules (1)
- SOD1 (1)
- SPAQ (1)
- STAT (1)
- Satellite glial cell (1)
- Schmerz (1)
- Schwann cells (1)
- Sehnerv (1)
- Small fiber Neuropathie (1)
- Small fiber neuropathy (1)
- Smn (1)
- Spinal Muscular-arthropy (1)
- Spinal muscular atrophy (DLC) (1)
- Spinale Muskelathropie (1)
- Spinalganglion (1)
- Spliceosome (1)
- Stammzellen (1)
- Syap1 (1)
- Syap1 knockout (1)
- Syap1 localization (1)
- Synapse-associated protein (1)
- Synapsen assoziiert (1)
- Synaptische Transmission (1)
- T-cadherin (1)
- TBCE (1)
- TRP channel (1)
- TRPA1 (1)
- TRPA1 channel (1)
- Temporal-lobe epilepsy (1)
- Tiermodell (1)
- Tissue Engineering (1)
- Transgenic mice (1)
- Ultraschall (1)
- VCAM-1 (1)
- Valproat (1)
- Valproic acid (1)
- Valproinsäure (1)
- Vascular plasticity (1)
- Viability (1)
- Wachstum (1)
- YB-1 (1)
- Yb1 (1)
- Zelldifferenzierung (1)
- Zentrales Nervensystem (1)
- Zytokine (1)
- actin (1)
- actin messenger RNA (1)
- activation (1)
- adenocarcinoma of the lung (1)
- allosteric modulation (1)
- alpha-7 nicotinic acetylcholine receptor (1)
- amoeboid cell migration (1)
- analgesia (1)
- antibodies (1)
- antigen processing and recognition (1)
- anxiety (1)
- apoptosis (1)
- astrocytes (1)
- autism (1)
- autoantibodies (1)
- autoantibody (aAb) (1)
- autoimmune antibodies (1)
- autoimmune nodopathy (1)
- axon (1)
- axon growth (1)
- axonal transport (1)
- axonaler Transport (1)
- barrier (1)
- basal ganglia (1)
- behavioral disorders (1)
- beta-actin (1)
- bioimage analysis (1)
- biopsies (1)
- brain (1)
- brain cancer (1)
- breast cancer (1)
- c-Jun (1)
- cadherin-13 (CDH13) (1)
- calcium activity (1)
- calcium channels (1)
- calyx (1)
- cancer (1)
- candidate gene (1)
- cardiology (1)
- cell death (1)
- cell staining (1)
- cells (1)
- cerebellum (1)
- cerebral blood flow (1)
- channel (1)
- chick (1)
- choline acetyltransferase (1)
- chronic pain (1)
- ciliary neuron (1)
- ciliary-neurotrophic factor (1)
- circuits and circuit components (1)
- claudin-5 (1)
- click-chemistry (1)
- clinical neurology (1)
- cochlea (1)
- comet assay (1)
- compartimentalized cultures (1)
- contactin (1)
- cortico-striatal synapse (1)
- corticogenesis (1)
- cross-sectional studies (1)
- cytosol (1)
- dSPN (1)
- dSTORM (1)
- deep brain stimulation (1)
- degeneration (1)
- demyelination (1)
- dendrite (1)
- dentate gyrus (1)
- determining gene-product (1)
- direct pathway (1)
- domain (1)
- domain K\(^{+}\) channels (1)
- dominant (1)
- dorsal raphe (1)
- dorsal root ganglion (1)
- durotaxis (1)
- dynamics of ribosomal assembly (1)
- early-onset predictors (1)
- electron tomography (1)
- embryos (1)
- emotional states (1)
- energy metabolism (1)
- enrichment (1)
- epilepsy (1)
- exercise (1)
- facial nerve lesion (1)
- factor prevents (1)
- fast decay (1)
- fear (1)
- fluorescence in-situ hybridization (1)
- frontotemporal dementia (1)
- fused in sarcoma (1)
- gait (1)
- gel electrophoresis (1)
- gene expression (1)
- gene targeting (1)
- genetic code expansion (1)
- genome wide (1)
- gephyrin (1)
- glycine receptor (GlyR) (1)
- glycine transporter 2 (1)
- glycogen phosphorylase (1)
- glycogen synthase (1)
- glycolysis (1)
- glyvine uptake (1)
- granule cells (1)
- hearing loss (1)
- hippocampal neurons (1)
- hnRNP (1)
- hnRNP-Q (1)
- homologous recombination (1)
- human startle disease (1)
- hyaluronic acid (1)
- iPSC (induced pluripotent stem cells) (1)
- immune response (1)
- immune serum (1)
- immunocytochemical analysis (1)
- immunohistochemical (1)
- immunohistochemistry techniques (1)
- inflammatory demyelinating polyradiculoneuropathy (1)
- inflammatory neuropathy (1)
- inflammatory pain (1)
- inhibitory snapse (1)
- initiation (1)
- injury (1)
- insulin (1)
- insulin-likegrowth factor I (1)
- interaction partners (1)
- interacts (1)
- interleukin 6 (1)
- interspeific backcross (1)
- intrazelluläre Domäne (1)
- ion channels in the nervous system (1)
- knockout mice (1)
- kompartimentierte Kulturen (1)
- lIF (1)
- larval drosophila (1)
- library screening (1)
- ligand potencies (1)
- linalool (1)
- linalyl acetate (1)
- linkage (1)
- lithium (1)
- local protein synthesis (1)
- locomotion (1)
- loop B (1)
- lung and intrathoracic tumors (1)
- mRNA localization (1)
- machine learning (1)
- macrophages (1)
- mechanisms (1)
- medicine (1)
- memory (1)
- mesencephalic locomotor region (1)
- metastasis (1)
- microscopy (1)
- microtubules (1)
- migraine (1)
- migration (1)
- mild cognitive impairment (1)
- mimetic peptide (1)
- modulation (1)
- molecular mechanisms (1)
- molecular medicine (1)
- molecular neuroscience (1)
- monoclonal antibodies (1)
- morpholino knockdown (1)
- motoneuron (MN) (1)
- motor axon (1)
- motor axons (1)
- motor control (1)
- motor learning (1)
- motor neuron (1)
- motor neuron degeneration (1)
- motor neurons (1)
- motor neuropathy (1)
- mouse model (1)
- movement disorders (1)
- mulitple-sclerosis patients (1)
- musk myasthenia gravis (1)
- mutations (1)
- myelin (1)
- nerve injury (1)
- nerve lesion (1)
- nerve ultrasonography (1)
- nervous system (1)
- neural networks (1)
- neurite (1)
- neurodegeneration (1)
- neurodegenerative disorder (1)
- neurodevelopment (1)
- neurofilaments (1)
- neuroinflammation (1)
- neuron migration (1)
- neuronal dendrites (1)
- neuronal differentiation (1)
- neuronal excitability (1)
- neuronal network (1)
- neuronal networks (1)
- neuronal primary culture (1)
- neuronal survival and differentiation (1)
- neuronale Plastizität (1)
- neuropathy (1)
- neuropil (1)
- neuroscience (1)
- neurotrophe Faktoren (1)
- neurotrophic (1)
- neurotrophic factor (1)
- neurotrophic molecules (1)
- nifedipine (1)
- nociception (1)
- node of ranvier (1)
- non-small cell lung cancer (1)
- nonneuronaI cells (1)
- nuclear ribonucleoprotein-R (1)
- ontactin 1 (1)
- outer hair cell (OHC) (1)
- oxidized phospholipids (1)
- oxygenation (1)
- pain therapy (1)
- passive transfer (1)
- patch clamp recording (1)
- patch-clamp (1)
- pegylated insulin-like growth factor 1 (1)
- periperal nerve (1)
- peripheral neuropathy (1)
- phosphorylase isozymes (1)
- photothrombotic stroke (1)
- pmn-Maus (1)
- postsynaptic potentials (1)
- posttranslational modifications (1)
- prefrontal cortex (1)
- presynapse (1)
- presynaptic ER dynamics (1)
- primary notoneuron (1)
- primäre Motoneurone (1)
- programmed cell death (1)
- progressive encephalitis with rigidity and myoclonus (PERM) (1)
- protein coupled receptors (1)
- protein interactions (1)
- protein maturation (1)
- protein synthesis (1)
- protein transport (1)
- psychiatric disorders (1)
- pyridoxal phosphatase (PDXP) (1)
- quality control (1)
- radial glia (1)
- rat (1)
- recombinant proteins (1)
- regulation (1)
- rescue (1)
- restriction fragment length polymorphism (1)
- roles (1)
- secondary lung tumors (1)
- self-activation (1)
- sensory neurons (1)
- serotonin (1)
- shaky mouse (1)
- short-term memory (1)
- side chain properties (1)
- silver staining (1)
- site (1)
- skeletal muscle (1)
- snRNP (1)
- sodium channel (1)
- software (1)
- spastic (1)
- spinal cord neurons (1)
- spontaneous excitation (1)
- spontaneous mouse mutants (1)
- startle (1)
- startle reaction (1)
- stathmin (1)
- stiff person syndrome (1)
- stiff-person syndrome (SPS) (1)
- stroke (1)
- subcellular trafficking (1)
- super-resolution microscopy (SRM) (1)
- superficial peroneal nerve (1)
- sural nerve (1)
- survey (1)
- survival (1)
- switch (1)
- synapse structure (1)
- synapses (1)
- synaptic localization (1)
- synaptic proteins (1)
- synaptic transmission (1)
- synaptisches Protein (1)
- synthase (1)
- systems biology (1)
- telemedicine (1)
- therapeutic antibody (1)
- thoracic diaphragm (1)
- tight junction (1)
- topotaxis (1)
- trafficking (1)
- trafficking pathways (1)
- transactivation (1)
- transport (1)
- trophic/potassium deprivation (1)
- tyrosine kinase (1)
- ultrasound (1)
- uper-resolution array tomography (1)
- vasculitis (1)
- vector cloning (1)
- vitamin B6 (1)
- α-synuclein-specific T cells (1)
- β-Aktin (1)
- β-actin (1)
- β-actin mRNA (1)
- β8-β9 loop (1)
Institute
- Institut für Klinische Neurobiologie (155) (remove)
Introduction
IgG4 autoantibodies against paranodal proteins are known to induce acute-onset and often severe sensorimotor autoimmune neuropathies. How autoantibodies reach their antigens at the paranode in spite of the myelin barrier is still unclear.
Methods
We performed in vitro incubation experiments with patient sera on unfixed and unpermeabilized nerve fibers and in vivo intraneural and intrathecal passive transfer of patient IgG to rats, to explore the access of IgG autoantibodies directed against neurofascin-155 and contactin-1 to the paranodes and their pathogenic effect.
Results
We found that in vitro incubation resulted in weak paranodal binding of anti-contactin-1 autoantibodies whereas anti-neurofascin-155 autoantibodies bound to the nodes more than to the paranodes. After short-term intraneural injection, no nodal or paranodal binding was detectable when using anti-neurofascin-155 antibodies. After repeated intrathecal injections, nodal more than paranodal binding could be detected in animals treated with anti-neurofascin-155, accompanied by sensorimotor neuropathy. In contrast, no paranodal binding was visible in rats intrathecally injected with anti-contactin-1 antibodies, and animals remained unaffected.
Conclusion
These data support the notion of different pathogenic mechanisms of anti-neurofascin-155 and anti-contactin-1 autoantibodies and different accessibility of paranodal and nodal structures.
Vitamin B6 deficiency has been linked to cognitive impairment in human brain disorders for decades. Still, the molecular mechanisms linking vitamin B6 to these pathologies remain poorly understood, and whether vitamin B6 supplementation improves cognition is unclear as well. Pyridoxal phosphatase (PDXP), an enzyme that controls levels of pyridoxal 5’-phosphate (PLP), the co-enzymatically active form of vitamin B6, may represent an alternative therapeutic entry point into vitamin B6-associated pathologies. However, pharmacological PDXP inhibitors to test this concept are lacking. We now identify a PDXP and age-dependent decline of PLP levels in the murine hippocampus that provides a rationale for the development of PDXP inhibitors. Using a combination of small molecule screening, protein crystallography and biolayer interferometry, we discover and analyze 7,8-dihydroxyflavone (7,8-DHF) as a direct and potent PDXP inhibitor. 7,8-DHF binds and reversibly inhibits PDXP with low micromolar affinity and sub-micromolar potency. In mouse hippocampal neurons, 7,8-DHF increases PLP in a PDXP-dependent manner. These findings validate PDXP as a druggable target. Of note, 7,8-DHF is a well-studied molecule in brain disorder models, although its mechanism of action is actively debated. Our discovery of 7,8-DHF as a PDXP inhibitor offers novel mechanistic insights into the controversy surrounding 7,8-DHF-mediated effects in the brain.
Highlights
• Dopamine receptor-1 activation induces TrkB cell-surface expression in striatal neurons
• Dopaminergic deficits cause TrkB accumulation and clustering in the ER
• TrkB clusters colocalize with cargo receptor SORCS-2 in direct pathway striatal neurons
• Intracellular TrkB clusters fail to fuse with lysosomes after dopamine depletion
Summary
Disturbed motor control is a hallmark of Parkinson’s disease (PD). Cortico-striatal synapses play a central role in motor learning and adaption, and brain-derived neurotrophic factor (BDNF) from cortico-striatal afferents modulates their plasticity via TrkB in striatal medium spiny projection neurons (SPNs). We studied the role of dopamine in modulating the sensitivity of direct pathway SPNs (dSPNs) to BDNF in cultures of fluorescence-activated cell sorting (FACS)-enriched D1-expressing SPNs and 6-hydroxydopamine (6-OHDA)-treated rats. DRD1 activation causes enhanced TrkB translocation to the cell surface and increased sensitivity for BDNF. In contrast, dopamine depletion in cultured dSPN neurons, 6-OHDA-treated rats, and postmortem brain of patients with PD reduces BDNF responsiveness and causes formation of intracellular TrkB clusters. These clusters associate with sortilin related VPS10 domain containing receptor 2 (SORCS-2) in multivesicular-like structures, which apparently protects them from lysosomal degradation. Thus, impaired TrkB processing might contribute to disturbed motor function in PD.
The signals that coordinate and control movement in vertebrates are transmitted from motoneurons (MNs) to their target muscle cells at neuromuscular junctions (NMJs). Human NMJs display unique structural and physiological features, which make them vulnerable to pathological processes. NMJs are an early target in the pathology of motoneuron diseases (MND). Synaptic dysfunction and synapse elimination precede MN loss suggesting that the NMJ is the starting point of the pathophysiological cascade leading to MN death. Therefore, the study of human MNs in health and disease requires cell culture systems that enable the connection to their target muscle cells for NMJ formation. Here, we present a human neuromuscular co-culture system consisting of induced pluripotent stem cell (iPSC)-derived MNs and 3D skeletal muscle tissue derived from myoblasts. We used self-microfabricated silicone dishes combined with Velcro hooks to support the formation of 3D muscle tissue in a defined extracellular matrix, which enhances NMJ function and maturity. Using a combination of immunohistochemistry, calcium imaging, and pharmacological stimulations, we characterized and confirmed the function of the 3D muscle tissue and the 3D neuromuscular co-cultures. Finally, we applied this system as an in vitro model to study the pathophysiology of Amyotrophic Lateral Sclerosis (ALS) and found a decrease in neuromuscular coupling and muscle contraction in co-cultures with MNs harboring ALS-linked SOD1 mutation. In summary, the human 3D neuromuscular cell culture system presented here recapitulates aspects of human physiology in a controlled in vitro setting and is suitable for modeling of MND.
The neuronal RNA-binding protein Ptbp2 regulates neuronal differentiation by modulating alternative splicing programs in the nucleus. Such programs contribute to axonogenesis by adjusting the levels of protein isoforms involved in axon growth and branching. While its functions in alternative splicing have been described in detail, cytosolic roles of Ptbp2 for axon growth have remained elusive. Here, we show that Ptbp2 is located in the cytosol including axons and growth cones of motoneurons, and that depletion of cytosolic Ptbp2 affects axon growth. We identify Ptbp2 as a major interactor of the 3’ UTR of Hnrnpr mRNA encoding the RNA-binding protein hnRNP R. Axonal localization of Hnrnpr mRNA and local synthesis of hnRNP R protein are strongly reduced when Ptbp2 is depleted, leading to defective axon growth. Ptbp2 regulates hnRNP R translation by mediating the association of Hnrnpr with ribosomes in a manner dependent on the translation factor eIF5A2. Our data thus suggest a mechanism whereby cytosolic Ptbp2 modulates axon growth by fine-tuning the mRNA transport and local synthesis of an RNA-binding protein.
Bioimages frequently exhibit low signal-to-noise ratios due to experimental conditions, specimen characteristics, and imaging trade-offs. Reliable segmentation of such ambiguous images is difficult and laborious. Here we introduce deepflash2, a deep learning-enabled segmentation tool for bioimage analysis. The tool addresses typical challenges that may arise during the training, evaluation, and application of deep learning models on ambiguous data. The tool’s training and evaluation pipeline uses multiple expert annotations and deep model ensembles to achieve accurate results. The application pipeline supports various use-cases for expert annotations and includes a quality assurance mechanism in the form of uncertainty measures. Benchmarked against other tools, deepflash2 offers both high predictive accuracy and efficient computational resource usage. The tool is built upon established deep learning libraries and enables sharing of trained model ensembles with the research community. deepflash2 aims to simplify the integration of deep learning into bioimage analysis projects while improving accuracy and reliability.
Glycine receptor β–targeting autoantibodies contribute to the pathology of autoimmune diseases
(2024)
Background and Objectives
Stiff-person syndrome (SPS) and progressive encephalomyelitis with rigidity and myoclonus (PERM) are rare neurologic disorders of the CNS. Until now, exclusive GlyRα subunit–binding autoantibodies with subsequent changes in function and surface numbers were reported. GlyR autoantibodies have also been described in patients with focal epilepsy. Autoimmune reactivity against the GlyRβ subunits has not yet been shown. Autoantibodies against GlyRα1 target the large extracellular N-terminal domain. This domain shares a high degree of sequence homology with GlyRβ making it not unlikely that GlyRβ-specific autoantibody (aAb) exist and contribute to the disease pathology.
Methods
In this study, we investigated serum samples from 58 patients for aAb specifically detecting GlyRβ. Studies in microarray format, cell-based assays, and primary spinal cord neurons and spinal cord tissue immunohistochemistry were performed to determine specific GlyRβ binding and define aAb binding to distinct protein regions. Preadsorption approaches of aAbs using living cells and the purified extracellular receptor domain were further used. Finally, functional consequences for inhibitory neurotransmission upon GlyRβ aAb binding were resolved by whole-cell patch-clamp recordings.
Results
Among 58 samples investigated, cell-based assays, tissue analysis, and preadsorption approaches revealed 2 patients with high specificity for GlyRβ aAb. Quantitative protein cluster analysis demonstrated aAb binding to synaptic GlyRβ colocalized with the scaffold protein gephyrin independent of the presence of GlyRα1. At the functional level, binding of GlyRβ aAb from both patients to its target impair glycine efficacy.
Discussion
Our study establishes GlyRβ as novel target of aAb in patients with SPS/PERM. In contrast to exclusively GlyRα1-positive sera, which alter glycine potency, aAbs against GlyRβ impair receptor efficacy for the neurotransmitter glycine. Imaging and functional analyses showed that GlyRβ aAbs antagonize inhibitory neurotransmission by affecting receptor function rather than localization.
Human startle disease is associated with mutations in distinct genes encoding glycine receptors, transporters or interacting proteins at glycinergic synapses in spinal cord and brainstem. However, a significant number of diagnosed patients does not carry a mutation in the common genes GLRA1, GLRB, and SLC6A5. Recently, studies on solute carrier 7 subfamily 10 (SLC7A10; Asc-1, alanine-serine-cysteine transporter) knock-out (KO) mice displaying a startle disease-like phenotype hypothesized that this transporter might represent a novel candidate for human startle disease. Here, we screened 51 patients from our patient cohort negative for the common genes and found three exonic (one missense, two synonymous), seven intronic, and single nucleotide changes in the 5′ and 3′ untranslated regions (UTRs) in Asc-1. The identified missense mutation Asc-1\(^{G307R}\) from a patient with startle disease and developmental delay was investigated in functional studies. At the molecular level, the mutation Asc-1\(^{G307R}\) did not interfere with cell-surface expression, but disrupted glycine uptake. Substitution of glycine at position 307 to other amino acids, e.g., to alanine or tryptophan did not affect trafficking or glycine transport. By contrast, G307K disrupted glycine transport similar to the G307R mutation found in the patient. Structurally, the disrupted function in variants carrying positively charged residues can be explained by local structural rearrangements because of the large positively charged side chain. Thus, our data suggest that SLC7A10 may represent a rare but novel gene associated with human startle disease and developmental delay.
Der Glycin-Rezeptor ist Teil der inhibitorischen liganden-gesteuerten Ionenkanäle im ZNS und wird am stärksten im adulten Rückenmark sowie im Hirnstamm exprimiert. In der Nerv-Muskel-Synapse sind GlyR für die rekurrente Hemmung der Motoneuronen wichtig und steuern das Gleichgewicht zwischen Erregung und Hemmung der Muskelzellen. Für die glycinerge Neurotransmission sind neben den präsynaptischen GlyR 𝛼1 insbesondere postsynaptische GlyR 𝛼1/𝛽 verantwortlich. Durch Mutationen des GlyR entsteht das Erkrankungsbild der Hyperekplexie mit übersteigerter Schreckhaftigkeit, Muskelsteifheit und Apnoe. Hauptursächlich dafür sind Mutationen im GLRA1-Gen. Die shaky Maus stellt ein gutes Modell zur Erforschung dieser seltenen Erkrankung dar.
Die shaky Missense-Mutation Q177K in der extrazellulären 𝛽8-𝛽9 Schleife der Glycin- Rezeptor-𝛼1-Untereinheit zeigte strukturell ein gestörtes Wasserstoffbrückennetzwerk. Funktionell konnten eingeschränkt leitfähige Ionenkanäle identifiziert werden. Der letale Phänotyp äußert sich beim homozygoten shaky Tier durch Schrecksymptome mit einem einhergehenden zunehmenden Gewichtsverlust. Die Quantifizierung der Oberflächenexpression deutete auf einen Verlust synaptischer GlyR 𝛼1/𝛽 hin. Aussagen bezüglich der GlyR-𝛽-Untereinheit, die Teil des synaptischen GlyR Komplexes ist, waren aufgrund fehlender stabiler Antikörper bisher nicht möglich. Das neuartige KI- Mausmodell Glrb eos exprimiert endogen fluoreszierende 𝛽 -Untereinheiten und ermöglicht damit erstmalig eine Betrachtung der GlyR- 𝛽-Expression in Tiermodellen der Startle Erkrankung.
Ziel dieser Arbeit war es, die Auswirkungen der shaky Mutation auf die Interaktion mit der 𝛽 -Untereinheit und Gephyrin zu erforschen. Dafür wurden Markerproteine der glycinergen Synapse in Rückenmarksneuronen der Kreuzung Glrb eos x Glra1 sh gefärbt und quantifiziert. Die durchgeführte Gewichtsbestimmung der Nachkommen im zeitlichen Verlauf zeigte keinen Einfluss der eingefügten mEos4b-Sequenz auf das Körpergewicht der Tiere und schließt damit funktionelle Einschränkungen bedingt durch die mEos4b-Sequenz aus. Zur Verstärkung des 𝛽 eos-Signals wurde ein Antikörper verwendet. Die Quantifizierung der GlyR- 𝛽- Untereinheit an Rückenmarksneuronen zeigte für homozygote shaky Tiere im Vergleich zum Wildtyp signifikant reduzierte 𝛽eos Oberflächenexpressionen in Gephyrin Clustern sowie signifikant erniedrigte Kolokalisationen von Gephyrin/𝛼1, 𝛽eos/𝛼1 und 𝛽eos/Gephyrin. Die mutierte GlyR-𝛼1- Untereinheit wurde hingegen vermehrt an der Oberfläche in shaky Tieren exprimiert. Die Ergebnisse der Rückenmarksschnitte unterstützen diese Befunde aus den Primärneuronen. Die Untersuchung der Präsynapse erbrachte für Glrb eos/eos x Glra1 sh/sh eine signifikant verminderte Synapsin und Synapsin/𝛼1 Expression.
Die Ergebnisse dieser Arbeit erweitern die Daten früherer Arbeiten zur shaky Maus und zeigen einen starken Verlust synaptischer GlyR 𝛼 1/ 𝛽 an der Oberfläche von Motoneuronen. Ein möglicher kompensatorischer Versuch durch erhöhte 𝛼1 Expression bleibt infolge der Funktionsbeeinträchtigung dieser mutierten GlyR- 𝛼 1 Rezeptoren erfolglos mit letalem Ausgang. In vorherigen Arbeiten wurde vermutet, dass die Mutation in der extrazellulären Bindungsstelle in der Lage ist, Konformationsänderungen in die TM3-TM4-Schleifenstruktur zu übertragen und dadurch die Gephyrin Bindung und synaptische Verankerung zu stören. Die Daten dieser Arbeit stützen diese Annahme und weisen darüber hinaus auf eine gestörte Rezeptorkomplexbindung hin. Die vorliegende Arbeit trägt somit zum besseren Verständnis der Startle Erkrankung auf synaptischer Ebene bei.
Motor neuron diseases (MNDs) encompass a variety of clinically and genetically heterogeneous disorders, which lead to the degeneration of motor neurons (MNs) and impaired motor functions. MNs coordinate and control movement by transmitting their signal to a target muscle cell. The synaptic endings of the MN axon and the contact site of the muscle cell thereby form the presynaptic and postsynaptic structures of the neuromuscular junction (NMJ). In MNDs, synaptic dysfunction and synapse elimination precede MN loss suggesting that the NMJ is an early target in the pathophysiological cascade leading to MN death. In this study, we established new experimental strategies to analyze human MNDs by patient derived induced pluripotent stem cells (iPSCs) and investigated pathophysiological mechanisms in two different MNDs.
To study human MNDs, specialized cell culture systems that enable the connection of MNs to their target muscle cells are required to allow the formation of NMJs. In the first part of this study, we established and validated a human neuromuscular co-culture system consisting of iPSC derived MNs and 3D skeletal muscle tissue derived from myoblasts. We generated 3D muscle tissue by culturing primary myoblasts in a defined extracellular matrix in self-microfabricated silicone dishes that support the 3D tissue formation. Subsequently, iPSCs from healthy donors and iPSCs from patients with the progressive MND Amyotrophic Lateral Sclerosis (ALS) were differentiated into MNs and used for 3D neuromuscular co-cultures. Using a combination of immunohistochemistry, calcium imaging, and pharmacological stimulations, we characterized and confirmed the functionality of the 3D muscle tissue and the 3D neuromuscular co-cultures. Finally, we applied this system as an in vitro model to study the pathophysiology of ALS and found a decrease in neuromuscular coupling, muscle contraction, and axonal outgrowth in co-cultures with MNs harboring ALS-linked superoxide dismutase 1 (SOD1) mutation. In summary, this co-culture system presents a human model for MNDs that can recapitulate aspects of ALS pathophysiology.
In the second part of this study, we identified an impaired unconventional protein secretion (UPS) of Sod1 as pathological mechanisms in Pleckstrin homology domain-containing family G member 5 (Plekhg5)-associated MND. Sod1 is a leaderless cytosolic protein which is secreted in an autophagy-dependent manner. We found that Plekhg5 depletion in primary MNs and NSC34 cells leads to an impaired secretion of wildtype Sod1, indicating that Plekhg5 drives the UPS of Sod1 in vitro. By interfering with different steps during the biogenesis of autophagosomes, we could show that Plekhg5-regulated Sod1 secretion is determined by autophagy. To analyze our findings in a clinically more relevant model we utilized human iPSC MNs from healthy donors and ALS patients with SOD1 mutations. We observed reduced SOD1 secretion in ALS MNs which coincides with reduced protein expression of PLEKHG5 compared to healthy and isogenic control MNs. To confirm this correlation, we depleted PLEKHG5 in control MNs and found reduced extracellular SOD1 levels, implying that SOD1 secretion depends on PLEKHG5. In summary, we found that Plekh5 regulates the UPS of Sod1 in mouse and human MNs and that Sod1 secretion occurs in an autophagy dependent manner. Our data shows an unreported mechanistic link between two MND-associated proteins.
In the face of threat, animals react with a defensive reaction to avoid or reduce harm. This defensive reaction encompasses apart from behavioral changes also physiological, analgetic, and endocrine adaptations. Nonetheless, most animal studies on fear and anxiety are based on behavioral observations only, disregarding other aspects of the defensive reaction, or integrating their inter-related dynamics only insufficiently. The first part of this thesis aimed in characterizing patterned associations of behavioral and physiological responses, termed integrated defensive states. Analyzing cardiac and behavioral responses in mice undergoing multiple fear and anxiety paradigms revealed a complex and dynamic interaction of those readouts on both, short and long timescales. Microstates, stereotypical combinations of i.e. freezing and decelerating heart rates, are short-lasting and were, in turn, shown to be influenced by slow acting macrostate changes. One of those higher order macrostates, called `rigidity`, was defined as a latent process that constrains the range of momentary displayed heart rate values. Furthermore, integrated defensive states were found to be highly dependent on the cue and the context the animals are confronted with. Importantly, same behavioral observations, i.e. freezing, were associated with distinct cardiac responses, highlighting the importance of multivariate analysis of integrated defensive states. Defensive states are orchestrated by the brain, which has evolved evolutionary conserved survival circuits. A central brain area of these circuits is the periaqueductal gray (PAG) in the midbrain. It plays a pivotal role in mediating defensive states, as it receives signals about external and internal information from multiple brain regions and sends information to both, higher order brain areas as well as to the brainstem ultimately causing the execution of threat responses. In the second part of this thesis, different neuronal circuit elements in the PAG were optically manipulated in order to gain mechanistic insight into the defense network in the brain underlying the previously delineated cardio-behavioral defensive states. Optical activation of glutamatergic PAG neurons evoked heterogeneous, light-intensity dependent responses. However, a further molecular restriction of the glutamatergic neuronal population targeting only Chx10+ neurons, led to a cardio-behavioral state that resembled spontaneous freezing-bradycardia bouts.
In summary, this thesis presents a multivariate description of defensive states, which includes the complex interaction of cardiac and behavioral responses on different timescales and, furthermore, functionally dissects different excitatory and inhibitory PAG circuit elements mediating these defensive states.
In spinal muscular atrophy (SMA), mutations in or loss of the Survival Motor Neuron 1 (SMN1) gene reduce full-length SMN protein levels, which leads to the degeneration of a percentage of motor neurons. In mouse models of SMA, the development and maintenance of spinal motor neurons and the neuromuscular junction (NMJ) function are altered. Since nifedipine is known to be neuroprotective and increases neurotransmission in nerve terminals, we investigated its effects on cultured spinal cord motor neurons and motor nerve terminals of control and SMA mice. We found that application of nifedipine increased the frequency of spontaneous Ca\(^{2+}\) transients, growth cone size, cluster-like formations of Cav2.2 channels, and it normalized axon extension in SMA neurons in culture. At the NMJ, nifedipine significantly increased evoked and spontaneous release at low-frequency stimulation in both genotypes. High-strength stimulation revealed that nifedipine increased the size of the readily releasable pool (RRP) of vesicles in control but not SMA mice. These findings provide experimental evidence about the ability of nifedipine to prevent the appearance of developmental defects in SMA embryonic motor neurons in culture and reveal to which extent nifedipine could still increase neurotransmission at the NMJ in SMA mice under different functional demands.
Der Einfluss des Ciliary Neurotrophic Factor (CNTF) auf die mikroskopische Anatomie des Sehnervs und der Retina wurde im Mausmodell untersucht. Unter Verwendung von Immunhistochemie, konfokaler Lasermikroskopie und Elektronenmikroskopie wurde untersucht, inwieweit eine CNTF-Defizienz zu degenerativen Veränderungen in Sehnerv und Retina von insbesondere adulten Mäusen führt. Hinsichtlich der verschiedenen untersuchten Parameter, einschließlich der Myelinisierung des Sehnervs und der retinalen Schichtung, konnten keine signifikanten Unterschiede zwischen CNTF-defizienten und Wild-Typ-Mäusen festgestellt werden.
Chronic pain conditions are a major reason for the utilization of the health care system. Inflammatory pain states can persist facilitated by peripheral sensitization of nociceptors. The voltage-gated sodium channel 1.9 (NaV1.9) is an important regulator of neuronal excitability and is involved in inflammation-induced pain hypersensitivity. Recently, oxidized 1-palmitoyl-2-arachidonoyl-sn-glycerol-3-phosphatidylcholine (OxPAPC) was identified as a mediator of acute inflammatory pain and persistent hyperalgesia, suggesting an involvement in proalgesic cascades and peripheral sensitization. Peripheral sensitization implies an increase in neuronal excitability. This thesis aims to characterize spontaneous calcium activity in neuronal compartments as a proxy to investigate neuronal excitability, making use of the computational tool Neural Activity Cubic (NA3). NA3 allows automated calcium activity event detection of signal-close-to-noise calcium activity and evaluation of neuronal activity states. Additionally, the influence of OxPAPC and NaV1.9 on the excitability of murine dorsal root ganglion (DRG) neurons and the effect of OxPAPC on the response of DRG neurons towards other inflammatory mediators (prostaglandin E2, histamine, and bradykinin) is investigated. Using calcium imaging, the presence of spontaneous calcium activity in murine DRG neurons was established. NA3 was used to quantify this spontaneous calcium activity, which revealed decreased activity counts in axons and somata of NaV1.9 knockout (KO) neurons compared to wildtype (WT). Incubation of WT DRG neurons with OxPAPC before calcium imaging did not show altered activity counts compared to controls. OxPAPC incubation also did not modify the response of DRG neurons treated with inflammatory mediators. However, the variance ratio computed by NA3 conclusively allowed to determine neuronal activity states. In conclusion, my findings indicate an important function of NaV1.9 in determining the neuronal excitability of DRG neurons in resting states. OxPAPC exposition does not influence neuronal excitability nor sensitizes neurons for other inflammatory mediators. This evidence reduces the primary mechanism of OxPAPC-induced hyperalgesia to acute effects. Importantly, it was possible to establish an approach for unbiased excitability quantification of DRG neurons by calcium activity event detection and calcium trace variance analysis by NA3. It was possible to show that signal-close-to-noise calcium activity reflects neuronal excitability states.
Survival motor neuron (SMN) is an essential and ubiquitously expressed protein that participates in several aspects of RNA metabolism. SMN deficiency causes a devastating motor neuron disease called spinal muscular atrophy (SMA). SMN forms the core of a protein complex localized at the cytoplasm and nuclear gems and that catalyzes spliceosomal snRNP particle synthesis. In cultured motor neurons, SMN is also present in dendrites and axons, and forms part of the ribonucleoprotein transport granules implicated in mRNA trafficking and local translation. Nevertheless, the distribution, regulation, and role of SMN at the axons and presynaptic motor terminals in vivo are still unclear. By using conventional confocal microscopy and STED super-resolution nanoscopy, we found that SMN appears in the form of granules distributed along motor axons at nerve terminals. Our fluorescence in situ hybridization and electron microscopy studies also confirmed the presence of β-actin mRNA, ribosomes, and polysomes in the presynaptic motor terminal, key elements of the protein synthesis machinery involved in local translation in this compartment. SMN granules co-localize with the microtubule-associated protein 1B (MAP1B) and neurofilaments, suggesting that the cytoskeleton participates in transporting and positioning the granules. We also found that, while SMN granules are physiologically downregulated at the presynaptic element during the period of postnatal maturation in wild-type (non-transgenic) mice, they accumulate in areas of neurofilament aggregation in SMA mice, suggesting that the high expression of SMN at the NMJ, together with the cytoskeletal defects, contribute to impairing the bi-directional traffic of proteins and organelles between the axon and the presynaptic terminal.
Objective
Alzheimer’s disease (AD) is a growing challenge worldwide, which is why the search for early-onset predictors must be focused as soon as possible. Longitudinal studies that investigate courses of neuropsychological and other variables screen for such predictors correlated to mild cognitive impairment (MCI). However, one often neglected issue in analyses of such studies is measurement invariance (MI), which is often assumed but not tested for. This study uses the absence of MI (non-MI) and latent factor scores instead of composite variables to assess properties of cognitive domains, compensation mechanisms, and their predictability to establish a method for a more comprehensive understanding of pathological cognitive decline.
Methods
An exploratory factor analysis (EFA) and a set of increasingly restricted confirmatory factor analyses (CFAs) were conducted to find latent factors, compared them with the composite approach, and to test for longitudinal (partial-)MI in a neuropsychiatric test battery, consisting of 14 test variables. A total of 330 elderly (mean age: 73.78 ± 1.52 years at baseline) were analyzed two times (3 years apart).
Results
EFA revealed a four-factor model representing declarative memory, attention, working memory, and visual–spatial processing. Based on CFA, an accurate model was estimated across both measurement timepoints. Partial non-MI was found for parameters such as loadings, test- and latent factor intercepts as well as latent factor variances. The latent factor approach was preferable to the composite approach.
Conclusion
The overall assessment of non-MI latent factors may pose a possible target for this field of research. Hence, the non-MI of variances indicated variables that are especially suited for the prediction of pathological cognitive decline, while non-MI of intercepts indicated general aging-related decline. As a result, the sole assessment of MI may help distinguish pathological from normative aging processes and additionally may reveal compensatory neuropsychological mechanisms.
3D neuronal cultures attempt to better replicate the in vivo environment to study neurological/neurodegenerative diseases compared to 2D models. A challenge to establish 3D neuron culture models is the low elastic modulus (30–500 Pa) of the native brain. Here, an ultra-soft matrix based on thiolated hyaluronic acid (HA-SH) reinforced with a microfiber frame is formulated and used. Hyaluronic acid represents an essential component of the brain extracellular matrix (ECM). Box-shaped frames with a microfiber spacing of 200 µm composed of 10-layers of poly(ɛ-caprolactone) (PCL) microfibers (9.7 ± 0.2 µm) made via melt electrowriting (MEW) are used to reinforce the HA-SH matrix which has an elastic modulus of 95 Pa. The neuronal viability is low in pure HA-SH matrix, however, when astrocytes are pre-seeded below this reinforced construct, they significantly support neuronal survival, network formation quantified by neurite length, and neuronal firing shown by Ca\(^{2+}\) imaging. The astrocyte-seeded HA-SH matrix is able to match the neuronal viability to the level of Matrigel, a gold standard matrix for neuronal culture for over two decades. Thus, this 3D MEW frame reinforced HA-SH composite with neurons and astrocytes constitutes a reliable and reproducible system to further study brain diseases.
The nervous system is shielded by special barriers. Nerve injury results in blood–nerve barrier breakdown with downregulation of certain tight junction proteins accompanying the painful neuropathic phenotype. The dorsal root ganglion (DRG) consists of a neuron-rich region (NRR, somata of somatosensory and nociceptive neurons) and a fibre-rich region (FRR), and their putative epi-/perineurium (EPN). Here, we analysed blood–DRG barrier (BDB) properties in these physiologically distinct regions in Wistar rats after chronic constriction injury (CCI). Cldn5, Cldn12, and Tjp1 (rats) mRNA were downregulated 1 week after traumatic nerve injury. Claudin-1 immunoreactivity (IR) found in the EPN, claudin-19-IR in the FRR, and ZO-1-IR in FRR-EPN were unaltered after CCI. However, laser-assisted, vessel specific qPCR, and IR studies confirmed a significant loss of claudin-5 in the NRR. The NRR was three-times more permeable compared to the FRR for high and low molecular weight markers. NRR permeability was not further increased 1-week after CCI, but significantly more CD68\(^+\) macrophages had migrated into the NRR. In summary, NRR and FRR are different in naïve rats. Short-term traumatic nerve injury leaves the already highly permeable BDB in the NRR unaltered for small and large molecules. Claudin-5 is downregulated in the NRR. This could facilitate macrophage invasion, and thereby neuronal sensitisation and hyperalgesia. Targeting the stabilisation of claudin-5 in microvessels and the BDB barrier could be a future approach for neuropathic pain therapy.
Background: Glioblastoma multiforme (GBM) and metastatic triple-negative breast cancer (TNBC) with PTEN mutations often lead to brain dissemination with poor patient outcome, thus new therapeutic targets are needed. To understand signaling, controlling the dynamics and mechanics of brain tumor cell migration, we implemented GBM and TNBC cell lines and designed 3D aligned microfibers and scaffolds mimicking brain structures. Methods: 3D microfibers and scaffolds were printed using melt electrowriting. GBM and TNBC cell lines with opposing PTEN genotypes were analyzed with RHO-ROCK-PTEN inhibitors and PTEN rescue using live-cell imaging. RNA-sequencing and qPCR of tumor cells in 3D with microfibers were performed, while scanning electron microscopy and confocal microscopy addressed cell morphology. Results: In contrast to the PTEN wildtype, GBM and TNBC cells with PTEN loss of function yielded enhanced durotaxis, topotaxis, adhesion, amoeboid migration on 3D microfibers and significant high RHOB expression. Functional studies concerning RHOB-ROCK-PTEN signaling confirmed the essential role for the above cellular processes. Conclusions: This study demonstrates a significant role of the PTEN genotype and RHOB expression for durotaxis, adhesion and migration dependent on 3D. GBM and TNBC cells with PTEN loss of function have an affinity for stiff brain structures promoting metastasis. 3D microfibers represent an important tool to model brain metastasizing tumor cells, where RHO-inhibitors could play an essential role for improved therapy.